In vivo stabilization of mutant human transthyretin in transgenic mice

References

• Buxbaum J N. The Amyloidoses. Rheumatology, S SWWSC Hochberg. Elsevier, London 2005; 2015–2026
   Google Scholar
• Kelly J W, Colon W, Lai Z, Lashuel H A, McCulloch J, McCutchen S L, Miroy G J, Peterson S A. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 1997; 50: 161–181
   PubMedGoogle Scholar
• Jacobson D R, McFarlin D E, Kane I, Buxbaum J N. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet 1992; 89: 353–356
   PubMed Web of Science ®Google Scholar
• Lashuel H A, Wurth C, Woo L, Kelly J W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 1999; 38: 13560–13573
   PubMed Web of Science ®Google Scholar
• McCutchen S L, Lai Z, Miroy G J, Kelly J W, Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995; 34: 13527–13536
   PubMed Web of Science ®Google Scholar
• McCutchen S L, Colon W, Kelly J W. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 1993; 32: 12119–12127
   PubMed Web of Science ®Google Scholar
• Teng M H, Gallo G, Buxbaum J. Is an amyloidogenic substrate enough? Transgenic mice producing human TTR Pro55 do not develop amyloid. Neuromusc Disord 1996; 6(Suppl. 1)S30
   Google Scholar
• Teng M H, Yin J Y, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson D R, Tagoe C, Gallo G, Buxbaum J. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 2001; 81: 385–396
   PubMed Web of Science ®Google Scholar
• Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris G A, Gottesman M E, Robertson E J. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 1993; 90: 2375–2379
   PubMed Web of Science ®Google Scholar
• Ritchie R F, Palomaki G E, Neveux L M, Navolotskaia O. Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature. J Clin Lab Anal 1999; 13: 280–286
   PubMedGoogle Scholar
• Vranckx R, Savu L, Maya M, Rouaze-Romet M, Nunez E A. Immunological quantitation of rat and mouse thyroxine-binding globulins. Ontogenesis and sex-dependence of the circulating levels of the thyroxine-binding globulins. Acta Endocrinol 1990; 123: 649–656
   PubMedGoogle Scholar
• Lipman R D, Gaillard E T, Harrison D E, Bronson R T. Husbandry factors and the prevalence of age-related amyloidosis in mice. Lab Anim Sci 1993; 43: 439–444
   PubMedGoogle Scholar
• Picken M M, Gallo G R, Frangione B. Amyloid enhancing factor and inflammatory reaction. Lab Invest 1990; 63: 586–587
   PubMedGoogle Scholar
• Reixach N, Deechongkit S, Jiang X, Kelly J W, Buxbaum J N. Tissue damage in the amyloidoses: transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004; 101: 2817–2822
   PubMed Web of Science ®Google Scholar
• Reixach N, Adamski-Werner S L, Kelly J W, Koziol J, Buxbaum J N. Cell based screening of inhibitors of transthyretin aggregation. Biochem Biophys Res Commun 2006; 348: 889–897
   PubMed Web of Science ®Google Scholar
• Adamski-Werner S L, Palaninathan S K, Sacchettini J C, Kelly J W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004; 47: 355–374
   PubMed Web of Science ®Google Scholar
• Yan C, Costa R H, Darnell J E, Jr, Chen J D, Van Dyke T A. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J 1990; 9: 869–878
   PubMedGoogle Scholar
• Kohno K, Palha J A, Miyakawa K, Saraiva M J, Ito S, Mabuchi T, Blaner W S, Iijima H, Tsukahara S, Episkopou V, Gottesman M E, Shimada K, Takahashi K, Yamamura K, Maeda S. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 1997; 150: 1497–1508
   PubMed Web of Science ®Google Scholar
• Takeda T, Hosokawa M, Higuchi K, Hosono M, Akiguchi I, Katoh H. A novel murine model of aging, Senescence-Accelerated Mouse (SAM). Arch Gerontol Geriatr 1994; 19: 185–192
   PubMed Web of Science ®Google Scholar
• Sousa M, Fernandes R, Palha J, Taboada A, Vieira P, Saraiva M. Evidence for early cytotoxicity aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 2002; 161: 1935–1948
   PubMed Web of Science ®Google Scholar
• Sousa M M, Cardoso I, Fernandes R, Guimaraes A, Saraiva M J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001; 159: 1993–2000
   PubMed Web of Science ®Google Scholar
• Skinner M, Connors L H, Rubinow A, Libbey C, Sipe J D, Cohen A S. Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their non-affected but at risk relatives. Am J Med Sci 1985; 289: 17–21
   PubMed Web of Science ®Google Scholar
• Benson M D, Dwulet F E. Prealbumin and retinol binding protein serum concentrations in the Indiana type hereditary amyloidosis. Arthritis Rheum 1983; 26: 1493–1498
   PubMed Web of Science ®Google Scholar
• Kelly J W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998; 8: 101–106
   PubMed Web of Science ®Google Scholar
• Hammarström P, Jiang X, Hurshman A R, Powers E T, Kelly J W. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002; 99(Suppl. 4)16427–16432
   PubMedGoogle Scholar
• Hammarstrom P, Schneider F, Kelly J W. Trans-suppression of misfolding in an amyloid disease. Science 2001; 293: 2459–2462
   PubMed Web of Science ®Google Scholar
• Coelho T, Chorao R, Sousa A, Alves I, Torres M F, Saraiva M JM. Compound heterozygotes of transthyretin MET 30 and transthyretin MET 119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromusc Disord 1996; 6(Suppl. 1)S20
   Google Scholar
• Schreiber G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 2002; 175: 61–73
   PubMed Web of Science ®Google Scholar
• Tojo K, Sekijima Y, Kelly J W, Ikeda S I. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006; 56: 441–449
   PubMed Web of Science ®Google Scholar